Literature DB >> 8213352

Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. II. Identification of (tissue) macrophages as the IL-1 producing cells and the effect of anti-inflammatory drugs.

J Dawson1, C Rordorf-Adam, T Geiger, H Towbin, S Kunz, H Nguyen, O Zingel, D Chaplin, K Vosbeck.   

Abstract

We have used our newly described mouse tissue chamber model [1], to investigate the process of IL-1 production in more detail. The inflammatory reaction in the tissue surrounding the implanted chambers was investigated histologically and by using the polymerase chain reaction (PCR). The inflammatory response included influx of leucocytes into the granuloma surrounding the tissue chamber, expression of IL-1 beta on macrophages present in the inflamed tissue and an increase in the mRNA coding for IL-1 beta and IL-6 proteins in the granuloma. The effects of three anti-inflammatory or immunosuppressive drugs, prednisolone, indomethacin and cyclosporin A, on IL-1 beta and PGE2 production in zymosan and Bordetella-pertussis-vaccine (BPV)-challenged tissue chambers were also examined. Oral treatment with prednisolone and cyclosporin A of zymosan-challenged animals showed a dose-dependent reduction of IL-1 beta concentrations, but no effect of indomethacin. Both prednisolone and indomethacin dose-dependently reduced PGE2 concentrations to control levels, while cyclosporin A was effective only at the highest dose tested (100 mg/kg/day p.o.). In drug-treated BPV-challenged animals, prednisolone and cyclosporin A also showed a dose-dependent reduction of IL-1 beta, while indomethacin was again ineffective. Prednisolone and indomethacin also dose-dependently reduced the PGE2 concentrations to control levels, whereas cyclosporin A was effective only at the highest dose tested (100 mg/kg/day p.o.). This model will be useful for investigating the mechanisms controlling the production of IL-1 beta from the mRNA level to the secretion of mature biologically active protein [1], and in the search for new drugs which could selectively interfere with this process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8213352     DOI: 10.1007/bf01976218

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  6 in total

1.  Occurrence of interleukin-1 in human synovial fluid: detection by RIA, bioassay and presence of bioassay-inhibiting factors.

Authors:  J B Smith; M H Bocchieri; L Sherbin-Allen; M Borofsky; J L Abruzzo
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

2.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

Authors:  J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

Review 3.  Models of arthritis and the search for anti-arthritic drugs.

Authors:  M E Billingham
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

4.  Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. I. Development and initial characterisation of the model.

Authors:  J Dawson; C Rordorf-Adam; T Geiger; H Towbin; S Kunz; H Nguyen; O Zingel; D Chaplin; K Vosbeck
Journal:  Agents Actions       Date:  1993-03

5.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

6.  In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse.

Authors:  L J Murray; R Lee; C Martens
Journal:  Eur J Immunol       Date:  1990-01       Impact factor: 5.532

  6 in total
  6 in total

1.  Differential effects of prednisolone and indomethacin on zymosan-induced inflammation in a modified murine tissue-chamber model.

Authors:  A O Oluyomi; H Nguyen; H Towbin; J Dawson; K Vosbeck
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

2.  Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia.

Authors:  B Safieh-Garabedian; S Poole; A Allchorne; J Winter; C J Woolf
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

3.  Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice.

Authors:  K Török; K Németh; F Erdö; P Arányi; J I Székely
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

4.  Measurement of interleukin-1 liberation in zymosan air-pouch exudate in mice.

Authors:  F Erdö; K Török; J I Székely
Journal:  Agents Actions       Date:  1994-03

5.  Glucocorticoid-mediated enhancement of glutamatergic transmission may outweigh anti-inflammatory effects under conditions of neuropathic pain.

Authors:  Glenn-Marie Le Coz; Fernand Anton; Ulrike Hanesch
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

6.  Secreted Gaussia princeps luciferase as a reporter of Escherichia coli replication in a mouse tissue cage model of infection.

Authors:  Mingyu Liu; Christina Blinn; Sarah M McLeod; John W Wiseman; Joseph V Newman; Stewart L Fisher; Grant K Walkup
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.